Companies Dominating the Immunoglobulin (IgG) Replacement Therapy Landscape
- Boehringer Ingelheim
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Grifols, S.A.
- Octapharma AG
- CSL Limited
- BDI Pharma Inc.
- China Biologics Products Inc.
- Abeona Therapeutics
- Baxter International Inc.
- Kedrion Biopharma
- LFB Group
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Immunoglobulin Replacement Therapy Market in 2025 is assessed at USD 14.31 billion.
The global market size was worth more than USD 13.51 billion in 2024 and is poised to witness a CAGR of around 7.4%, crossing USD 34.18 billion revenue by 2037.
North America is likely to generate USD 12.3 billion by 2037, attributed to well-developed healthcare infrastructure and the prevalence of diseases requiring immunoglobulin therapies.
The major players in the market include Boehringer Ingelheim, Grifols, S.A., Octapharma AG, CSL Limited, BDI Pharma Inc., China Biologics Products Inc., Abeona Therapeutics, Baxter International Inc., Kedrion Biopharma, LFB Group, Takeda Pharmaceutical Company Limited, Alexion Pharma LLC., Daiichi Sankyo Co Ltd., CSL Behring Co. Ltd., Teijin Pharma Co., Ltd.
